Celldex Therapeutics’ (CLDX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report published on Monday morning, Benzinga reports. They currently have a $80.00 target price on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. Citigroup began coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. The Goldman Sachs Group started coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target on the stock. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $62.25.

Celldex Therapeutics Trading Down 1.0 %

NASDAQ:CLDX opened at $26.06 on Monday. The company has a market cap of $1.73 billion, a P/E ratio of -9.51 and a beta of 1.55. Celldex Therapeutics has a twelve month low of $22.26 and a twelve month high of $53.18. The company’s 50-day moving average price is $35.12 and its 200-day moving average price is $36.34.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The business had revenue of $2.50 million for the quarter, compared to analyst estimates of $1.13 million. On average, analysts expect that Celldex Therapeutics will post -2.5 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Celldex Therapeutics by 16.3% in the 4th quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock valued at $120,817,000 after buying an additional 427,827 shares during the period. Novo Holdings A S boosted its holdings in Celldex Therapeutics by 13.4% in the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after purchasing an additional 113,663 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Celldex Therapeutics by 631.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after purchasing an additional 2,664,915 shares in the last quarter. Swiss National Bank grew its stake in Celldex Therapeutics by 17.8% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock worth $4,797,000 after purchasing an additional 17,300 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in Celldex Therapeutics by 3,327.0% during the 1st quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock worth $28,879,000 after purchasing an additional 668,002 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.